Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Associated Therapies: -

Clinical Trials

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Stage I Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma
CD20 Positive
Stage IV Diffuse Large B-Cell Lymphoma
Stage II Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Carfilzomib
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Rituximab

First Posted Date: 2013-10-10

Last Posted Date: 2024-08-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 29

Registration Number: NCT01959698

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

Phase 1

Completed

Conditions: Solid Tumors
Hematologic Malignancies
Hepatic Impairment

Interventions: Drug: Carfilzomib

First Posted Date: 2013-09-24

Last Posted Date: 2017-05-02

Lead Sponsor: Amgen

Target Recruit Count: 46

Registration Number: NCT01949545

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

and more 8 locations

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

Phase 1

Completed

Conditions: Relapsed Multiple Myeloma
End-stage Renal Disease

Interventions: Drug: Carfilzomib

First Posted Date: 2013-09-24

Last Posted Date: 2017-05-02

Lead Sponsor: Amgen

Target Recruit Count: 26

Registration Number: NCT01949532

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital, Lake Success, New York, United States

and more 10 locations

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Phase 1

Completed

Conditions: Non Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Irinotecan Sensitive Cancers

Interventions: Drug: Carfilzomib
Drug: Irinotecan

First Posted Date: 2013-09-13

Last Posted Date: 2024-05-09

Lead Sponsor: Cancer Research and Biostatistics Clinical Trials Consortium

Target Recruit Count: 78

Registration Number: NCT01941316

Locations: 🇺🇸
Virginia Mason Cancer Institute, Seattle, Washington, United States
🇺🇸
Aurora Research Institute | Aurora Cancer Care, Wauwatosa, Wisconsin, United States
🇺🇸
Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, Arizona, United States

and more 5 locations

Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2013-08-21

Last Posted Date: 2017-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01926665

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-07-19

Last Posted Date: 2024-12-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 143

Registration Number: NCT01903811

Locations: 🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Illinois CancerCare-Princeton, Princeton, Illinois, United States
🇺🇸
John Muir Medical Center-Concord Campus, Concord, California, United States

and more 480 locations

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Other: Quality-of-Life Assessment
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-05-29

Last Posted Date: 2024-11-28

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 1087

Registration Number: NCT01863550

Locations: 🇺🇸
FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States
🇺🇸
Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
🇺🇸
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States

and more 913 locations

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2013-05-20

Last Posted Date: 2024-11-13

Lead Sponsor: European Myeloma Network B.V.

Target Recruit Count: 63

Registration Number: NCT01857115

Locations: 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: DS Stage I Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carfilzomib
Other: Laboratory Biomarker Analysis
Drug: Melphalan

First Posted Date: 2013-04-29

Last Posted Date: 2020-09-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT01842308

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Bortezomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2013-03-26

Last Posted Date: 2019-08-26

Lead Sponsor: Amgen

Target Recruit Count: 955

Registration Number: NCT01818752

Locations: 🇺🇸
California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States
🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia

and more 209 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy